TELO missed EPS expectations by 92.16%
Feb 13, 2025, 11:34 PM
0.00%
What does TELO do
Telomir Pharmaceuticals, a preclinical-stage company based in Tampa, Florida, focuses on developing TELOMIR-1 to lengthen DNA's telomere caps for age reversal. It went public on February 9, 2024.
Telomir Pharmaceuticals (TELO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Telomir Pharmaceuticals's actual EPS was -$0.10, missing the estimate of -$0.05 per share, resulting in a -92.16% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.